CHD

Church & Dwight is expected to report Q3 2026 earnings on October 30, with Wall Street forecasting EPS of $0.90 (up 11.1% YoY) but revenues declining 0.2% to $1.58 billion. The company has a positive Earnings ESP of +0.06% with a Zacks Rank #3 (Hold), suggesting a likely earnings beat. The stock has beaten consensus estimates in 3 of the last 4 quarters.

Procter & Gamble is prioritizing product innovation, AI integration, and brand superiority to accelerate organic sales growth. Key successes include double-digit Baby Care growth in China and Tide's return to growth. Competitors Church & Dwight, Colgate-Palmolive, and Clorox are similarly investing in innovation pipelines and premiumization strategies to strengthen market positions, though PG faces challenges with modest 1% organic sales growth in FY26.

Newell Brands reported Q2 2026 net sales growth of 3% to $2B, marking its first year-over-year growth in four years, driven by innovation and improved retail execution across multiple business units and brands. BJ's Wholesale Club, Church & Dwight, and Colgate-Palmolive also demonstrated strong sales momentum through customer growth, product innovation, and market-share gains, though inflationary pressures and uneven consumer spending remain headwinds.

With 10-year Treasury yields at 5.3%, the author argues that three dividend stocks offer better long-term value than bonds due to their growing dividend streams and earnings potential over a decade. Church & Dwight, Nike, and Hormel Foods are presented as alternatives that can compound income over time, despite near-term risks for some.

Colgate-Palmolive is strengthening its market position through innovation, premiumization of oral-care products, and expansion in emerging markets. The company is introducing differentiated products targeting whitening, sensitivity, and gum health, while leveraging its strong global brands.

However, sustaining momentum depends on balancing pricing with volume, successful product launches, and cost management. Colgate trades at a premium valuation (21.5X forward P/E vs. industry 18.4X) with modest EPS growth projected at 4.9% for 2026 and 5.2% for 2027.